Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Clinical Trial of Bortezomib (Velcade) + Pemetrexed (Alimta) in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

NCT00516100 is registered in ClinicalTrials.gov with Aptium Oncology Research Network as lead sponsor.

NCT NCT00516100
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00516100 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Clinical Trial of Bortezomib (Velcade) + Pemetrexed (Alimta) in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
Lead sponsor
Aptium Oncology Research Network
Phase
Phase 1/2
Overall status
Unknown status
Start date
January 31, 2006
Completion date
August 31, 2012
Enrollment
62 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer